Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

被引：32
|
作者：
Speer, Michael E. [1 ]
Fernandes, Caraciolo J. [1 ]
Boron, Marnie [2 ]
Groothuis, Jessie R. [2 ]
机构：
[1] Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
[2] Medimmune Inc, Gaithersburg, MD 20878 USA
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2008年 / 27卷 / 06期
关键词：
cystic fibrosis; RSV; palivizumab; hospitalization;
D O I：
10.1097/INF.0b013e3181673c15
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received >= 1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.
引用
下载
收藏
页码：559 / 561
页数：3
相关论文
共 50 条
  • [1] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Candice Bjornson
    Parco Chan
    Abby Li
    Bosco Paes
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
  • [2] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson, Candice
    Chan, Parco
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    Mitchell, Ian
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (06) : 1113 - 1118
  • [3] Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations
    Bjornson, Candice
    Chan, Parco
    Li, Abby
    Paes, Bosco
    Lanctot, Krista
    Mitchell, Ian
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children with Cystic Fibrosis
    Winterstein, Almut G.
    Eworuke, Efe
    Xu, Dandan
    Schuler, Pamela
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 148 - 148
  • [5] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Bosco Paes
    Mahwesh Saleem
    Doyoung Kim
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1561 - 1568
  • [6] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Paes, Bosco
    Saleem, Mahwesh
    Kim, Doyoung
    Lanctot, Krista L.
    Mitchell, Ian
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (08) : 1561 - 1568
  • [7] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
  • [8] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
  • [9] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian
    Mckoy, Naomi
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (02):
  • [10] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    Mckoy, Naomi A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
12345